Drug
Efx
Efx: highest development phase Phase 2, developed by Akero Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Akero Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| EFX NCT05039450 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
| EFX NCT03976401 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
Latest
No recent events.
Follow Efx on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.